Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients

NCT ID: NCT01672463

Last Updated: 2023-03-29

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1
• Total Enrollment: 31 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-12-31
• Study Completion Date: 2023-10-31

Brief Summary

This is an open label Phase 1b clinical trial of IV administration of OKN-007 in a pilot cohort of human recurrent malignant glioma patients. All patients will have been previously treated with the standard-of-care treatment which includes surgical resection, radiation and chemotherapy, and in some cases treatment for recurrent disease with investigational agents or bevacizumab (Avastin). Patients with unequivocal recurrence (first or greater) established by MRI with and without contrast (e.g., Gd-DTPA (Gadolinium-diethylene triamine pentacetic acid) and meeting inclusion and exclusion criteria, will be eligible for OKN-007 treatment on this protocol.

Conditions

Recurrent Malignant Glioma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

All patients

All participants enrolled in this study

Group Type: EXPERIMENTAL

OKN-007

Intervention Type: DRUG

Dose escalation/PK cohort: 20 mg/kg, 40 mg/kg or 60 mg/kg OKN-007 via IV infusion, given 3x/week for the first 4 weeks, then 2x/week for the next 4 weeks, then 1x/week thereafter.

Expansion cohort: MTD via IV infusion given 3x/week for the first 4 weeks, then 2x/week for the next 4 weeks, then 1x/week thereafter.

Interventions

OKN-007

Dose escalation/PK cohort: 20 mg/kg, 40 mg/kg or 60 mg/kg OKN-007 via IV infusion, given 3x/week for the first 4 weeks, then 2x/week for the next 4 weeks, then 1x/week thereafter.

Expansion cohort: MTD via IV infusion given 3x/week for the first 4 weeks, then 2x/week for the next 4 weeks, then 1x/week thereafter.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Confirmed histopathology of WHO grade III glioma or WHO grade IV GBM at primary diagnosis

2. Unequivocal radiographic evidence of tumor progression by MRI within 14 days prior to registration

3. Prior radiotherapy

4. Prior Temozolomide treatment

5. Last cytotoxic chemotherapy 28 or more days or biologic therapy treatment 14 or more days before study start (greater than or equal to 42 days if nitrosourea was administered)

6. Karnofsky performance status greater than or equal to 60%

7. Full recovery (< grade 1) from the toxic effects of any earlier intervention and a minimum of 28 days from the administration of any investigational agent

8. Adequate renal, liver and bone marrow function:

• Leukocytes >3,000/mcL
• Absolute neutrophil count >1,500/mcL
• Platelets >100,000/mcL
• Total bilirubin within normal limits
• AST / ALT (SGPT) <2.5 x ULN
• Creatinine within normal limits

9. Patients must be >_18 years of age

Exclusion Criteria

1. Second primary malignancy (except adequately treated basal cell carcinoma of the skin). Patients who had another malignancy in the past, but have been free of active disease for more than 2 years, are eligible

2. Have received treatment within the last 28 days with a drug that has not received regulatory approval for any indication at the time of study entry

3. Serious concomitant systemic disorders (for example, active infection or abnormal electrocardiogram (ECG) indicative of cardiac disease) that, in the opinion of the investigator, would compromise the safety of the patient and his/her ability to complete the study

4. Patients with moderate or severe renal impairment (calculated creatinine clearance of < 60 mL/min)

5. Patients with sodium, potassium, or creatinine serum electrolytes > grade 2.

6. Patients with PT/PTT above the upper limit of normal

7. Screening ECG abnormality documented by the investigator as medically significant

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Oblato, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

James Battiste, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

• Oklahoma University

Locations

Oklahoma University

Oklahoma City, Oklahoma, United States

Countries

United States

Other Identifiers

HCI57337

Identifier Type: -

Identifier Source: org_study_id